Streetbeat News

Regulatory

CDNA

The SEC has concluded its investigation into CareDx, Inc. and does not intend to recommend any enforcement action against the company. The investigation was related to matters similar to those identified in the civil investigative demand by the Department of Justice, with which the company continues to cooperate.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 11:05 am

GDTC

CytoMed Therapeutics has been granted a patent by the China National Intellectual Property Administration for its exclusively licensed Induced Pluripotent Stem Cell-based technology. The US-listed company GDTC is mentioned in the article.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 11:02 am

VAPO

Vapotherm, Inc. (NYSE:VAPO) announced the results of a clinical trial showing that its high velocity therapy products reduced the need for escalation of therapy and hospital stay duration in children with acute severe asthma. The study was presented at the European Respiratory Society International Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:47 am

MMM

3M Belgium is considering restarting idled PFAS manufacturing processes at its Zwijndrecht facility, according to a recent filing. The company is also exploring other options to accelerate the discontinuance of PFAS manufacturing at the facility. The decision comes amid regulatory matters with government agencies regarding safety measures related to PFAS emissions. The company is unable to predict the ultimate scope and extent of any negative impact to its operations due to uncertainties surrounding the idling of the manufacturing processes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:26 am

ABBV

GMAB

Genmab and AbbVie have received approval from the Japan Ministry of Health, Labour and Welfare for EPKINLY (epcoritamab), the first and only T-cell engaging bispecific antibody treatment in Japan. The drug is part of the companies' oncology collaboration.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 10:12 am

AAPL

GM

TSLA

The weekend news roundup includes a potential U.S. government shutdown, Elon Musk's intention to buy the iPhone 15, and speculations about the 2024 Presidential race. Musk, the CEO of Tesla, has also criticized the compensation of General Motors' CEO Mary Barra. The potential government shutdown could impact the careers of prominent figures such as Reps. Matt Gaetz and Marjorie Taylor Greene.

Portfolio Pulse from Benzinga Neuro

September 25, 2023 | 10:09 am

AIG

AIVAF

CRBG

Corebridge Financial Inc (NYSE:CRBG) has agreed to sell its UK life insurance business, AIG Life Limited, to Aviva PLC (OTC:AIVAF) for £460 million in cash. The sale is expected to close in H1 2024, subject to regulatory approvals. This move is part of Corebridge's strategy to focus on its core US portfolio. As of June 30, 2023, the company's liquidity stood at $1.6 billion.

Portfolio Pulse from Lekha Gupta

September 25, 2023 | 9:46 am

SNY

The Japanese Ministry of Health, Labor, and Welfare has approved Sanofi's Altuviiio, a Factor VIII replacement therapy for controlling bleeding tendency in patients with Hemophilia A.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 9:23 am

ARDX

Ardelyx, Inc. (NASDAQ:ARDX) announced that its partner, Kyowa Kirin, has received approval from the Japanese Ministry of Health for the New Drug Application for tenapanor, a kidney disease drug. This approval triggers $30 million in milestone payments from Kyowa Kirin to Ardelyx and a $5 million payment from HealthCare Royalty Partners. Ardelyx may also receive an additional $5 million if net sales in Japan exceed a certain target by 2025.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:22 am

EWG

Germany's current assessment for September is reported at 88.7, slightly above the estimated 88 but lower than the prior 89.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 8:08 am